Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
Campone, M., Bondarenko, I., Brincat, S., Hotko, Y., Munster, P.N., Chmielowska, E., Fumoleau, P., Ward, R., Bardy-Bouxin, N., Leip, E., Turnbull, K., Zacharchuk, C., Epstein, R.J.
Published in Annals of oncology (01.03.2012)
Published in Annals of oncology (01.03.2012)
Get full text
Journal Article
Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
Isakoff, S J, Wang, D, Campone, M, Calles, A, Leip, E, Turnbull, K, Bardy-Bouxin, N, Duvillié, L, Calvo, E
Published in British journal of cancer (25.11.2014)
Published in British journal of cancer (25.11.2014)
Get full text
Journal Article
Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer
Chan, Stephen, Scheulen, Max E., Johnston, Stephen, Mross, Klaus, Cardoso, Fatima, Dittrich, Christian, Eiermann, Wolfgang, Hess, Dagmar, Morant, Rudolph, Semiglazov, Vladimir, Borner, Markus, Salzberg, Marc, Ostapenko, Valerijus, Illiger, Hans-Joachim, Behringer, Dirk, Bardy-Bouxin, Nathalie, Boni, Joseph, Kong, Steven, Cincotta, Maria, Moore, Laurence
Published in Journal of clinical oncology (10.08.2005)
Published in Journal of clinical oncology (10.08.2005)
Get full text
Journal Article
PF415 EFFICACY AND SAFETY FOLLOWING DOSE REDUCTION OF BOSUTINIB IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA: ANALYSIS OF THE PHASE 4 BYOND TRIAL
Brümmendorf, T.H., Giles, F., Gambacorti‐Passerini, C., Roboz, G.J., Le Coutre, P., Hjorth‐Hansen, H., Stenke, L., Cervantes, F., Rousselot, P., Viqueira, A., Bardy‐Bouxin, N., Leip, E., Leone, J.M., Steegmann, J.L., Cortes, J.E., Hochhaus, A.
Published in HemaSphere (01.06.2019)
Published in HemaSphere (01.06.2019)
Get full text
Journal Article
PS1176 PRIMARY RESULTS OF THE PHASE 4 BYOND STUDY OF BOSUTINIB FOR PRETREATED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
Hochhaus, A., Gambacorti‐Passerini, C., Abboud, C., Gjertsen, B.T., Brümmendorf, T.H., Smith, B.D., Giraldo‐Castellano, P., Strömberg, U., Saussele, S., Bardy‐Bouxin, N., Viqueira, A., Leip, E., Leone, J., Rosti, G., Watts, J., Giles, F.
Published in HemaSphere (01.06.2019)
Published in HemaSphere (01.06.2019)
Get full text
Journal Article
Bosutinib (BOS) and letrozole (LET) versus LET alone as first-line treatment in postmenopausal women with advanced breast cancer (ABC)
Chow, L., Xu, B., Dirix, L. Y., Moy, B., Leip, E., Bardy-Bouxin, N., Duvillie, L., Sarosiek, T.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor–positive (HR+) HER2-negative (HER2–) advanced breast cancer (ABC)
Moy, B., Lebrun, F., Bellet, M., Chow, L., Lang, I., Xu, B., Badwe, R. A., Hershman, D. L., Leip, E., Bardy-Bouxin, N., Duvillie, L., Neven, P.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
Response to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib
Bardy-Bouxin, Nathalie, Matczak, Ewa, Devgan, Geeta, Woloj, Mabel, Shapiro, Mark
Published in Biologics (01.01.2015)
Published in Biologics (01.01.2015)
Get full text
Journal Article
Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL
Gambacorti-Passerini, C., Kantarjian, H., Bruemmendorf, T., Martinelli, G., Baccarani, M., Fischer, T., Pogliani, E.M., Hewes, B., Volkert, A.D.G., Bardy-Bouxin, N., Cortes, J.
Published in Blood (16.11.2007)
Published in Blood (16.11.2007)
Get full text
Journal Article
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
Campone, M, Bondarenko, I, Brincat, S, Hotko, Y, Munster, P N, Chmielowska, E, Fumoleau, P, Ward, R, Bardy-Bouxin, N, Leip, E, Turnbull, K, Zacharchuk, C, Epstein, R J
Published in Annals of oncology (01.03.2012)
Get full text
Published in Annals of oncology (01.03.2012)
Journal Article